Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) – A systematic review on potential biomarkers for neurodegeneration

Heller, Jan Erik; Brčina, Nikolina; Dogan, Imis; Holtbernd, Florian; Romanzetti, Sandro; Schulz, Jörg B.; Schiefer, Johannes; Reetz, Kathrin

doi:10.1016/j.smrv.2016.06.006

Cited by 83 publications

(55 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the degeneration of the pontine brainstem in SCA2 is in line with the early REM sleep pathology characterizing the disease from prodromal to manifest stage [35][36][37] since the neural circuit controlling this sleep stage lie mainly in the pontine brainstem. 38,39 In the present paper, we also observed a significant association between cerebellar volumes and Stroop interference task in the manifest SCA2 group but not in the preclinical subjects. This finding supports a cerebellar contribution to executive functions such as the ability to inhibit interfering stimuli and suggests disruptions of cerebello-thalamic-cortical projections, 40 in line with the profound degeneration of the thalamus in SCA2.…”

Section: Discussionsupporting

confidence: 69%

“…To our knowledge, this is the first work exploring the association of brain volumes and saccade velocity in SCA2. Besides, the degeneration of the pontine brainstem in SCA2 is in line with the early REM sleep pathology characterizing the disease from prodromal to manifest stage35, 36, 37 since the neural circuit controlling this sleep stage lie mainly in the pontine brainstem 38, 39…”

Section: Discussionmentioning

confidence: 73%

See 1 more Smart Citation

Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2

Reetz

Rodríguez‐Labrada²,

Dogan

et al. 2018

Ann Clin Transl Neurol

Self Cite

View full text Add to dashboard Cite

ObjectiveSpinocerebellar ataxia type 2 (SCA2) is an autosomal dominantly inherited neurodegenerative disease mainly affecting the cerebellum and brainstem. In this Cuban‐German research collaboration, we aimed to characterize atrophy patterns and associations with clinical measures in preclinical and manifest SCA2.MethodsIn this study, 16 nonmanifest SCA2 mutation carriers, 26 manifest patients with SCA2, and 18 healthy control subjects underwent magnetic resonance imaging, as well as genetic and clinical characterization including assessment of ataxia (Scale for the Assessment and Rating of Ataxia) and saccade velocity in Cuba were enrolled. Semiautomated quantitative volumetry of the cerebellum and brainstem, subdivided into the medulla oblongata, the pontine brainstem, and mesencephalon was performed. Additionally, the anteroposterior diameter of the pontine brainstem was measured.ResultsAnalysis of volumetric data revealed degeneration of the cerebellum and brainstem, in particular of pontine volumes and the anteroposterior diameter of the pons, in both manifest SCA2 patients and individuals at risk for SCA2 compared to controls. Comparing patients with nonataxic preclinical SCA2 mutation carriers, we found more pronounced reductions of the pontine brainstem and cerebellum in manifest SCA2. Volumetric data further showed associations with CAG repeat length and predicted age of onset in preclinical SCA2 individuals, and by trend with ataxia signs in patients. Although saccade velocity was associated with reduction in the pontine brainstem in preclinical and manifest SCA2, reduced ability to suppress interfering stimuli measured by the Stroop task was related to cerebellar volume loss in patients.InterpretationPreclinical SCA2 mutation carriers exhibit brain abnormalities, which could be targeted as surrogate parameters for disease progression and in future preventive trials.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 73%

Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2

Reetz

Rodríguez‐Labrada²,

Dogan

et al. 2018

Ann Clin Transl Neurol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Follow‐up studies reported that RBD patients are at almost equal risk of developing parkinsonism (PD or MSA) or dementia (DLB) first . Many neurodegeneration markers have been identified in RBD, notably autonomic, motor, color vision, olfaction, functional, and structural cerebral dysfunctions . However, most of these markers cannot distinguish the underlying synucleinopathy subtype.…”

Section: Discussionmentioning

confidence: 99%

How does dementia with Lewy bodies start? prodromal cognitive changes in REM sleep behavior disorder

Marchand

Postuma

Escudier

et al. 2018

Annals of Neurology

View full text Add to dashboard Cite

show abstract

“…Because idiopathic RBD is the strongest currently known predictor of PD, a growing number of studies have tried to identify reliable neuroimaging markers to predict the onset of parkinsonism in these prodromal individuals (43). Two studies demonstrated that idiopathic RBD patients significantly express the PDRP (44,45).…”

Section: Predicting Pd Onset In Idiopathic Rbdmentioning

confidence: 99%

Metabolic Imaging in Parkinson Disease

et al. 2016

View full text Add to dashboard Cite

This review focuses on recent human 18 F-FDG PET studies in Parkinson disease. First, an overview is given of the current analytic approaches to metabolic brain imaging data. Next, we discuss how 18 F-FDG PET studies have advanced understanding of the relation between distinct brain regions and associated symptoms in Parkinson disease, including cognitive decline. In addition, the value of 18 F-FDG PET studies in differential diagnosis, identifying prodromal patients, and the evaluation of treatment effects are reviewed. Finally, anticipated developments in the field are addressed.

show abstract

Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) – A systematic review on potential biomarkers for neurodegeneration

Cited by 83 publications

References 77 publications

Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2

Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2

How does dementia with Lewy bodies start? prodromal cognitive changes in REM sleep behavior disorder

Metabolic Imaging in Parkinson Disease

Contact Info

Product

Resources

About